Insider Brief Artificial intelligence is moving from laboratory experiments into the core infrastructure of drug discovery, healthcare delivery and preventive medicine, according to a new global study from Deep Knowledge Group that argues the next competitive divide will not be who develops AI models, but who can deploy them safely and at scale in life […]
Not because the money isn’t real. It isContinue reading on Medium »
Short reports are a blessing in disguise for any stock you’re holding. Someone with financial motivation and sufficient research capabilities has scoured the internet trying to find every single problem with an asset you’ve bought with your…
Nanotechnology is all about understanding things at the smallest unit of measurement possible. Like the oceans, we’re only beginning to explore how life works at a cellular level. Next-generation sequencing tools from Illumina $ILMN have allowed …
The promise of AI in pharma has been circulating for years. In 2025, the industry stopped talking about potential and started designing around it.
The post 2025: The Year Pharma Crossed the AI Threshold appeared first on Yseop.
Yseop’s first CMC-focused offering automates the Quality Overall Summary (Module 2.3), a central component of regulatory submissions that pulls structured insights from Module 3.2.
The post Yseop Expands into CMC: Redefining Regulatory Automation Beyond Clinical appeared first on Yseop.
Listen to the next episode of AI Uncovered with Karla Childers.
The post Karla Childers – Ethical Guardrails for AI in Pharma appeared first on Yseop.